Menu
Log in
Log in

News

  • Home
  • Resources
  • Literature Updates
  • Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

19 Feb 2020 11:16 AM | Deleted user

Charlotte I. Stroes, Sandor Schokker, Aafke Creemers, Remco J. Molenaar, Maarten C.C.M. Hulshof, Stephanie O. van der Woude, Roel J. Bennink, Ron A.A. Mathôt, Kausilia K. Krishnadath, Cornelis J.A. Punt, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Geert-Jan Creemers, Grard A.P. Nieuwenhuijzen, Maurice J.C. van der Sangen, Laurens V. Beerepoot, Joos Heisterkamp, Maartje Los, Marije Slingerland, Annemieke Cats, Geke A.P. Hospers, Maarten F. Bijlsma, Mark I. van Berge Henegouwen, Sybren L. Meijer, Hanneke W.M. van Laarhoven.

Click here to read the full abstract.

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization. © International Society for Disease of the Esophagus – ISDE 2024 | Any unauthorized use or reproduction of the content is prohibited without explicit permission.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software